Neogen Corporation(NEOG) Stock Research - Grey Stern Research
Loading...

Neogen Corporation (NEOG) Stock Analysis

$17.53 (1.68%)

NEOG Financial Performance


Use the table below to view Neogen Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $17.24 -
52 Week Low $11.46 -
52 Week High $20.89 -
Market Cap $3.7 Billion 8/15
Gross Margin 48% 6/15
Profit Margin -2% 8/15
EBITDA margin 20% 6/15
Q4 - 2024 Revenue $236.8 Million 8/15
Q4 - 2024 Earnings -$5.4 Million 9/15
Q4 - 2024 Free Cash Flow $2.4 Million 7/15
Trailing 4 Quarters Revenue $924.2 Million 8/15
Trailing 4 Quarters Earnings -$9.4 Million 9/15
Quarterly Earnings Growth -197% 14/15
Annual Earnings Growth -131% 13/15
Quarterly Revenue Growth -2% 13/15
Annual Revenue Growth 3% 6/15
Cash On Hand $170.6 Million 7/15
Short Term Debt $7.5 Million 9/15
Long Term Debt $888.4 Million 7/15

Neogen Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Neogen Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 9/15
PS 4.04 6/15
PB 1.19 12/15
PC 21.90 8/15
Liabilities to Equity 0.46 11/15
ROA 0.00 9/15
ROE 0.00 9/15
Current Ratio 3.18 5/15
Quick Ratio 0.12 11/15
Long Term Debt to Equity 0.28 7/15
Debt to Equity 0.29 8/15
Burn Rate 3.98 5/15
Cash to Cap 0.05 6/15
CCR -0.44 11/15
EV to EBITDA 96.29 2/15
EV to Revenue 4.84 6/15

Company Details

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

CEO: Mr. John Adent

Website: https://www.neogen.com

Address: 620 Lesher Pl Lansing, MICHIGAN

Exchange: NASDAQ Global Select

Industry: Diagnostics & Research

Neogen Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Neogen Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Syneos Health, Inc. SYNH $4.5 Billion
Qiagen N.V. QGEN $10.1 Billion
RadNet, Inc. RDNT $5.2 Billion
IQVIA Holdings Inc. IQV $44.6 Billion
ICON Public Limited Company ICLR $24.9 Billion
Medpace Holdings, Inc. MEDP $11.4 Billion
Myriad Genetics, Inc. MYGN $2.6 Billion
Aclaris Therapeutics, Inc. ACRS $86.3 Million
FONAR Corporation FONR $110.1 Million
Exagen Inc. XGN $49.6 Million
Burning Rock Biotech Limited BNR $35.6 Million
Sotera Health Company SHC $4.7 Billion
Olink Holding AB (publ) OLK $3.2 Billion
Sera Prognostics, Inc. SERA $252.7 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
NEOG Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 236.8 Million -$5.4 Million
Q3 2024 $ 228.8 Million -$2.0 Million
Q2 2024 $ 229.6 Million -$3.5 Million
Q1 2024 $ 229.0 Million $1.5 Million
Q4 2023 $ 241.8 Million $5.6 Million
Q3 2023 $ 218.3 Million $8.2 Million
Q2 2023 $ 230.0 Million -$41.8 Million
Q1 2023 $ 132.3 Million $5.2 Million

View All

NEOG Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $170.6 Million $4.6 Billion $906.2 Million $3.1 Billion
Q3 2024 $161.4 Million $4.6 Billion $890.2 Million $3.1 Billion
Q2 2024 $205.8 Million $4.6 Billion $889.5 Million $3.1 Billion
Q1 2024 $178.8 Million $4.6 Billion $886.2 Million $3.1 Billion
Q4 2023 $0 $4.6 Billion $0 $3.1 Billion
Q3 2023 $67.1 Million $4.5 Billion $884.7 Million $3.1 Billion
Q2 2023 $276.3 Million $4.6 Billion $924.0 Million $3.1 Billion
Q1 2023 $107.1 Million $977.4 Million $0 $883.8 Million

View All

NEOG Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 $2.4 Million -$24.3 Million $9.2 Million
Q3 2024 -$62.3 Million -$32.1 Million -$44.3 Million
Q2 2024 -$8.7 Million -$24.4 Million $26.9 Million
Q1 2024 $23.0 Million $0 $15.6 Million
Q4 2023 $65.5 Million -$25.5 Million $96.1 Million
Q3 2023 -$32.2 Million -$15.2 Million -$32.9 Million
Q2 2023 -$30.8 Million -$12.1 Million -$7.1 Million
Q1 2023 -$27.1 Million -$13.0 Million $62.6 Million

View All